Bladder cancer
Targeted therapies for metastatic UCa in special populations
Obiettivo della formazione: Get familiar with the current indications of immunotherapy and antibody-drug conjugates for metastatic urothelial carcinoma (UCa). Learn to identify patient characteristics that impact the appropriateness of immunotherapy and antibody-drug conjugates.
Specializzazione: Medical oncology, urology, clinical oncology, (radiation oncology)
Pubblico target: Specialists (CME: basic, intermediate), Residents (senior)
Aggiornamento più recente: May 2024
Premessa:
Regulatory approval status of drugs for metastatic UCa (status: 7 May 2024)
ChT: chemotherapy; CPS: combined positive score